8/ Sources 1. 2. 3. 4. 5. 6. 7. 8. 9. 10.…
8/ Sources
1. 2. 3. 4. 5. 6. 7. 8. 9. 10.…
6/ How Do we Measure Success: I’ll perform the following tests, implement my microdosing protocol, then retest after 12 weeks to determine success of the intervention. Metabolic Health: + Continuous glucose monitoring: Mean glucose, variability, peaks. + Insulin, HbA1c,…
6/ How Do we Measure Success:
I’ll perform the following tests, implement my microdosing protocol, then retest after 12 weeks to determine success of the intervention.
Metabolic Health:
+ Continuous glucose monitoring: Mean glucose, variability, peaks.
+ Insulin, HbA1c,…
7/ Conclusion Microdosing GLP-1-RAs represents a promising approach to leverage their potential longevity benefits while minimizing risks. Ongoing monitoring and consultation with healthcare professionals are crucial to ensure safety and efficacy.
7/ Conclusion
Microdosing GLP-1-RAs represents a promising approach to leverage their potential longevity benefits while minimizing risks. Ongoing monitoring and consultation with healthcare professionals are crucial to ensure safety and efficacy.
5/ Monitoring Potential Side Effects Even with microdosing, it’s essential to monitor for: Gastrointestinal Issues: Nausea and vomiting are common but less likely at low doses. Unintended Weight Loss: Increased satiety could lead to unintentional caloric restriction, I intend…
5/ Monitoring Potential Side Effects
Even with microdosing, it’s essential to monitor for:
Gastrointestinal Issues: Nausea and vomiting are common but less likely at low doses.
Unintended Weight Loss: Increased satiety could lead to unintentional caloric restriction, I intend…
3/ Possible Chronic Disease Risk Reduction Cardiovascular Health: semaglutide a GLP-1-RA has shown promise of lifespan extension in obese individuals by reducing the risk of cardiovascular disease. (12) Preclinical evidence also indicates improved endothelial function via…
3/ Possible Chronic Disease Risk Reduction
Cardiovascular Health: semaglutide a GLP-1-RA has shown promise of lifespan extension in obese individuals by reducing the risk of cardiovascular disease. (12)
Preclinical evidence also indicates improved endothelial function via…
4/ My Microdosing Protocol To evaluate the potential benefits I will start a 12 week trial of the GLP-1/GIP RA Tirzepatide (Commercial name: Munjaro for diabetes, Zepbound for weight loss). I'll start with a weekly dose of 0.5 mg, that is 1/2 the typical microdose, and 1/5 of…
4/ My Microdosing Protocol
To evaluate the potential benefits I will start a 12 week trial of the GLP-1/GIP RA Tirzepatide (Commercial name: Munjaro for diabetes, Zepbound for weight loss).
I'll start with a weekly dose of 0.5 mg, that is 1/2 the typical microdose, and 1/5 of…
1/ Here’s what I’m doing and why: What is a GLP-1RA? A GLP-1-RA is a medication that mimics the hormone glucagon-like peptide-1, crucial for regulating blood sugar and appetite. They’re approved for managing type 2 diabetes and aiding in weight loss by reducing blood sugar…
1/ Here’s what I’m doing and why:
What is a GLP-1RA? A GLP-1-RA is a medication that mimics the hormone glucagon-like peptide-1, crucial for regulating blood sugar and appetite. They’re approved for managing type 2 diabetes and aiding in weight loss by reducing blood sugar…
2/ Metabolic and Longevity Benefits Metabolic Optimization: Less glucose spikes, lower insulin levels, and thus reduced advanced glycation end-products (AGEs) (4, 5). Anti-Inflammatory Effects: Systemic inflammation reduction by decreasing pro-inflammatory cytokines like TNF-α…
2/ Metabolic and Longevity Benefits
Metabolic Optimization: Less glucose spikes, lower insulin levels, and thus reduced advanced glycation end-products (AGEs) (4, 5).
Anti-Inflammatory Effects: Systemic inflammation reduction by decreasing pro-inflammatory cytokines like TNF-α…
I'm starting a new longevity protocol: microdosing Tirzepatide, a dual GLP-1/GIP receptor agonist. Here is the existing evidence, my protocol, measurement plan, and what I expect to achieve by this intervention. 🧵
I'm starting a new longevity protocol: microdosing Tirzepatide, a dual GLP-1/GIP receptor agonist.
Here is the existing evidence, my protocol, measurement plan, and what I expect to achieve by this intervention. 🧵
6/ Complete lack of credibility, or any trace of sound reasoning. The study does not mention “oils” “cooking oils” or “plant oils” even once, it does mention “the western diet” once, and mentions Linoleic Acid and Arachidonic Acid, but all in the introduction, where the authors…
6/ Complete lack of credibility, or any trace of sound reasoning.
The study does not mention “oils” “cooking oils” or “plant oils” even once, it does mention “the western diet” once, and mentions Linoleic Acid and Arachidonic Acid, but all in the introduction, where the authors…
